Additional attention to combination antiretroviral therapy-related lipodystrophy

The occurrence of lipodystrophy in patients taking anti-human immunodeficiency virus (HIV) medications is a serious problem as it is irreversible even after drug withdrawal. Although it was first recognized in patients taking proteinase inhibitors, other types of anti-HIV agents can also cause lipod...

Full description

Saved in:
Bibliographic Details
Published inWorld Journal of Virology Vol. 6; no. 3; pp. 49 - 52
Main Authors Kobayashi, Norihiko, Nakahara, Masako, Oka, Masako, Saeki, Kumiko
Format Journal Article
LanguageEnglish
Japanese
Published United States Baishideng Publishing Group Inc 12.08.2017
Subjects
Field Of Vision
Lipodystrophy
Human immunodeficiency virus
Combination antiretroviral therapy
Reverse transcriptase inhibitor
Protease inhibitor
Online AccessGet full text

Cover

More Information
Summary:The occurrence of lipodystrophy in patients taking anti-human immunodeficiency virus (HIV) medications is a serious problem as it is irreversible even after drug withdrawal. Although it was first recognized in patients taking proteinase inhibitors, other types of anti-HIV agents can also cause lipodystrophy. In a recent publication by Jones et al entitled "Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes" in , it was reported that simultaneous treatment of human subcutaneous adipocytes with anti-HIV drugs with different mechanisms of action synergistically exerted anti-adipogenesis effects , warning us to take utmost care in every case receiving combination antiretroviral therapy (cART). For elucidation of the molecular basis for cART-related lipodystrophy, multi-faceted approaches should be taken, based on a deeper understanding of the development and organization of adipose tissues.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Telephone: +81-3-32027181 Fax: +81-3-32071038
Correspondence to: Kumiko Saeki, MD, PhD, Department of Disease Control, Research Institute, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. saeki@ri.ncgm.go.jp
Author contributions: Kobayashi N, Nakahara M and Oka M collected the materials and wrote the manuscript; Saeki K supervised the publication of this commentary.
ISSN:2220-3249
2220-3249
DOI:10.5501/wjv.v6.i3.49